Plasma concentrations of VCAM-1 and PAI-1: A predictive biomarker for post-operative recurrence in colorectal cancer

Cancer Science

Volumn 101, Issue 8, 2010, Pages 1886-1890

  Yamada, Yasuhide ^a   Arao, Tokuzo ^b   Matsumoto, Kazuko ^b   Gupta, Vinita ^c   Tan, Woei ^c   Fedynyshyn, Joe ^c   Nakajima, Takako E ^a   Shimada, Yasuhiro ^a   Hamaguchi, Tetsuya ^a   Kato, Ken ^a   Taniguchi, Hirokazu ^d   Saito, Yutaka ^e   Matsuda, Takahisa ^e   Moriya, Yoshihiro ^a   Akasu, Takayuki ^a   Fujita, Shin ^a   Yamamoto, Seiichiro ^a   Nishio, Kazuto ^b  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c BIO RAD LABORATORIES   (United States)

^d Chugai Pharmaceutical Chuo ku   (Japan)

^e Endoscopic Division   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; ANGIOPOIETIN RECEPTOR; ANTIBODY; BIOLOGICAL MARKER; CD31 ANTIGEN; ENDOSTATIN; FIBROBLAST GROWTH FACTOR 2; FOLLISTATIN; GELATINASE B; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 12; INTERLEUKIN 6 RECEPTOR; INTERLEUKIN 8; LEPTIN; MACROPHAGE MIGRATION INHIBITION FACTOR; PADGEM PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROUROKINASE; SCATTER FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; COLORECTAL CANCER; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR MARKERS, BIOLOGICAL; VASCULAR CELL ADHESION MOLECULE-1;

EID: 77954857105     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01595.x     Document Type: Article

References (27)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001, 51:15-36.
2. Ratto C, Sofo L, Ippoliti M, Merico M, Doglietto GB, Crucitti F. Prognostic factors in colorectal cancer. Literature review for clinical application. Dis Colon Rectum 1998, 41:1033-49.
3. Mutch MG. Molecular profiling and risk stratification of adenocarcinoma of the colon. J Surg Oncol 2007, 96:693-703.
4. Locker GY, Hamilton S, Harris J. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006, 24:5313-27.
5. Park YJ, Park KJ, Park JG, Lee KU, Choe KJ, Kim JP. Prognostic factors in 2230 Korean colorectal cancer patients: analysis of consecutively operated cases. World J Surg 1999, 23:721-6.
6. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998, 90:675-84.
7. Andreyev HJ, Norman AR, Cunningham D. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 2001, 85:692-6.
8. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005, 23:609-18.
9. Aschele C, Debernardis D, Lonardi S. Deleted in colon cancer protein expression in colorectal cancer metastases: a major predictor of survival in patients with unresectable metastatic disease receiving palliative fluorouracil-based chemotherapy. J Clin Oncol 2004, 22:3758-65.
10. Duffy MJ, van Dalen A, Haglund C. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use. Eur J Cancer 2007, 43:1348-60.
11. Kimura H, Kasahara K, Sekijima M, Tamura T, Nishio K. Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib. Lung Cancer 2005, 50:393-9.
12. Galkina E, Ley K. Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27:2292-301.
13. Carter RA, Wicks IP. Vascular cell adhesion molecule 1 (CD106): a multifaceted regulator of joint inflammation. Arthritis Rheum 2001, 44:985-94.
14. Yao M, Huang Y, Shioi K. A three-gene expression signature model to predict clinical outcome of clear cell renal carcinoma. Int J Cancer 2008, 123:1126-32.
15. De Cicco C, Ravasi L, Zorzino L. Circulating levels of VCAM and MMP-2 may help identify patients with more aggressive prostate cancer. Curr Cancer Drug Targets 2008, 8:199-206.
16. Silva HC, Garcao F, Coutinho EC, De Oliveira CF, Regateiro FJ. Soluble VCAM-1 and E-selectin in breast cancer: relationship with staging and with the detection of circulating cancer cells. Neoplasma 2006, 53:538-43.
17. Shioi K, Komiya A, Hattori K. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients. Clin Cancer Res 2006, 12:7339-46.
18. Shariat SF, Karam JA, Walz J. Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res 2008, 14:3785-91.
19. Wu TC. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 2007, 67:6003-6.
20. Durand MK, Bødker JS, Christensen A. Plasminogen activator inhibitor-I and tumour growth, invasion, and metastasis. Thromb Haemost 2004, 91:438-49.
21. Harbeck N, Schmitt M, Kates RE. Clinical utility of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 determination in primary breast cancer tissue for individualized therapy concepts. Clin Breast Cancer 2002, 3:196-200.
22. Harbeck N, Kates RE, Schmitt M. Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination. J Clin Oncol 2002, 20:1000-7.
23. Harris L, Fritsche H, Mennel R. American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 2007, 25:5287-312.
24. Herszènyi L, Plebani M, Carraro P. The role of cysteine and serine proteases in colorectal carcinoma. Cancer 1999, 86:1135-42.
25. Sier CF, Vloedgraven HJ, Ganesh S. Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology 1994, 107:1449-56.
26. Langenskiöld M, Holmdahl L, Angenete E, Falk P, Nordgren S, Ivarsson ML. Differential prognostic impact of uPA and PAI-1 in colon and rectal cancer. Tumour Biol 2009, 30(4):210-20.
27. Berger DH. Plasmin/plasminogen system in colorectal cancer. World J Surg 2002, 26:767-71.